Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin

19 Mar 2014

• By Emily Hayes

Related Content

Boehringer/Lilly To Price <i>Tradjenta</i> On Par With Rival DPP-4 Inhibitors

09 May 2011

AstraZeneca’s <em>Farxiga</em> Label Includes, But Downplays, Bladder Cancer Risk

13 Jan 2014

J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana

29 Mar 2013

Related Companies

Eli Lilly and Company

Boehringer Ingelheim GmbH

AstraZeneca PLC

Johnson & Johnson

Merck & Co., Inc.

Sanofi

Novo Nordisk A/S

Additional Topics

Manufacturing Regulation BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.